Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Integrated high capacity solid phase extraction-MS/MS system for pharmaceutical profiling in drug discovery.

Edward H Kerns1, Teresa Kleintop, David Little

  • 1Wyeth Research, CN8000, Princeton, NJ 08543-8000, USA. kernse@wyeth.com

Journal of Pharmaceutical and Biomedical Analysis
|January 24, 2004
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tacrolimus as Single-Agent Immunotherapy for Adult-Onset Myasthenia Gravis: Remission, Relapse, and Safety.

CNS neuroscience & therapeutics·2026
Same author

Biodistribution of Cerivastatin, Repaglinide, Glyburide, Rosuvastatin, and Valsartan in Cynomolgus Monkeys and PBPK Analysis.

The AAPS journal·2026
Same author

Clinical and laboratory features of juvenile-onset anti-NF155 autoimmune nodopathy.

Journal of neurology, neurosurgery, and psychiatry·2026
Same author

Rapid efficacy of efgartigimod for generalized myasthenia gravis patients in acute exacerbations/worsening: multicenter real-world retrospective study.

Journal of neurology·2026
Same author

Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir.

Drug metabolism and disposition: the biological fate of chemicals·2026
Same author

Effects of Thymectomy in Late-Onset Myasthenia Gravis: A Multi-Center Longitudinal Retrospective Study.

Annals of neurology·2025

This study introduces a novel analytical method for early drug discovery, enabling high-throughput pharmaceutical profiling. The technique enhances sample analysis speed and specificity without using analytical HPLC columns.

Area of Science:

  • Analytical Chemistry
  • Pharmaceutical Sciences
  • Mass Spectrometry

Background:

  • Early drug discovery requires efficient and specific analytical methods for compound profiling.
  • Existing methods can be time-consuming, limiting throughput in pharmaceutical research.
  • High-capacity analysis is crucial for evaluating drug candidates, particularly metabolic stability.

Purpose of the Study:

  • To describe a novel, high-capacity analytical method for pharmaceutical profiling of early drug discovery compounds.
  • To demonstrate the method's applicability for high-throughput analysis of metabolic stability samples.
  • To achieve high specificity and analysis rates without traditional analytical HPLC columns.

Main Methods:

  • Utilizes a high-capacity autosampler for sample injection.

Related Experiment Videos

  • Employs two parallel solid-phase extraction (SPE) columns for alternating trapping, washing, and elution.
  • Integrates with a tandem quadrupole mass spectrometer (MS/MS) operating in multiple reaction monitoring (MRM) mode.

    • Main Results:

    • Achieves an analysis rate of approximately 50 samples per hour.
    • A primary method covers 80-90% of compounds, with a secondary method for the remainder.
    • Specificity is ensured through MRM MS/MS analysis, eliminating the need for analytical HPLC columns.

    Conclusions:

    • The described method offers a significant advancement in high-capacity pharmaceutical profiling for early drug discovery.
    • It provides a rapid, specific, and efficient analytical solution for metabolic stability studies.
    • This approach streamlines compound analysis, accelerating the drug discovery process.